NATIONAL INSTITUTES OF HEALTH

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary, Private

Established: 1948-01-01

Employees: 1K

Market Cap: -

Website: http://www.nidcr.nih.gov

Clinical Trials

T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery

Phase 1

Terminated

Conditions: Breast Cancer
Brain Metastasis
Brain Cancer

Interventions: Drug: T-DM1
Drug: TMZ

First Posted Date: 2017-06-19

Last Posted Date: 2023-10-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 12

Registration Number: NCT03190967

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Effect of Isocaloric Ultra Processed Versus Unprocessed Diets on Insulin Sensitivity

Completed

Conditions: Obesity

First Posted Date: 2017-06-16

Last Posted Date: 2019-04-10

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 5

Registration Number: NCT03189121

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Collection of Malignant Ascites, Pleural Fluid, and Blood From People With Solid Tumors

Completed

Conditions: Ovarian Cancer
Primary Peritoneal Cancer
Cancer
Fallopian Tube Cancer

First Posted Date: 2017-06-16

Last Posted Date: 2025-05-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 22

Registration Number: NCT03189108

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Gastric Cancer Precursor Lesions (GCPL) Study

Completed

Conditions: Intestinal Metaplasia
Gastric Cancer

First Posted Date: 2017-06-15

Last Posted Date: 2020-12-19

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 1300

Registration Number: NCT03188406

Locations: 🇨🇱
Universidad de Concepción, Concepción, Chile
🇨🇱
Hospital de Curanilahue, Curanilahue, Chile
🇨🇱
Hospital San Juan de Dios, Santiago, Chile

and more 6 locations

Breadth of Donor Options for People With Inherited Diseases Requiring Allogeneic Hematopoietic Stem Cell Transplant in the Era of Alternative Donor Transplants Using Post-Transplantation Cyclophosphamide

Completed

Conditions: Common Variable Immunodeficiency
Primary T-cell Immunodeficiency Disorders

First Posted Date: 2017-06-15

Last Posted Date: 2020-02-21

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 161

Registration Number: NCT03188419

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer

Phase 2

Conditions: Prostatic Cancer
Prostate Cancer
Prostate Neoplasms
Cancer Of Prostate
Metastatic Prostate Cancer

Interventions: Drug: 18F-DCFPyL
Drug: PSMA-11
Drug: 18F-FDG

First Posted Date: 2017-06-09

Last Posted Date: 2025-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 330

Registration Number: NCT03181867

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Comparing One or Two Doses of the Human Papillomavirus Vaccine for the Prevention of Human Papillomavirus Infection, ESCUDDO Study

Phase 4

Active, not recruiting

Conditions: Human Papillomavirus Infection
Human Papillomavirus-Related Cervical Carcinoma

Interventions: Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Other: Questionnaire Administration
Biological: Recombinant Human Papillomavirus Nonavalent Vaccine
Biological: Recombinant Human Papillomavirus Bivalent Vaccine

First Posted Date: 2017-06-08

Last Posted Date: 2025-05-11

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28000

Registration Number: NCT03180034

Locations: 🇨🇷
Agencia Costarricense de Investigaciones Biomédicas (ACIB), Liberia, Guanacaste, Costa Rica

Cervix Image Sharing Protocol (CISP)

Completed

Conditions: Cervical Abnormalities
Cervical Cancer

First Posted Date: 2017-06-07

Last Posted Date: 2020-04-28

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 27084

Registration Number: NCT03179306

Locations: 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States

18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer

Phase 2

Active, not recruiting

Conditions: Metastatic Prostate Cancer
Prostatic Cancer
Prostate Neoplasms
Prostatic Neoplasms
Prostate Cancer

Interventions: Drug: 18F-NaF
Drug: 18F-DCFPyL
Drug: 18F-FDG

First Posted Date: 2017-06-02

Last Posted Date: 2025-05-31

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 96

Registration Number: NCT03173924

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers

Phase 2

Active, not recruiting

Conditions: Choroid Plexus Tumors
Ependymoma
Atypical/Malignant Meningioma
Medulloblastoma
Pineal Region Tumors

Interventions: Drug: Nivolumab

First Posted Date: 2017-06-02

Last Posted Date: 2025-05-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 133

Registration Number: NCT03173950

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸
Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy